Imatinib mesylate is a receptor tyrosine kinase inhibitor drug with broad applications in cancer therapeutics, for example, in chronic myeloid leukemia and gastrointestinal stromal tumors. In this study, new multi-omics findings in yeast on the mechanism of imatinib are reported, using the model organism Saccharomyces cerevisiae. Whole-genome analysis of the transcriptional response of yeast cells following long-term exposure to imatinib, flux-balance analysis (FBA), and modular analysis of protein/protein interaction network consisting of proteins encoded by differentially expressed genes (DEGs) were performed. DEGs indicated that carbon, nitrogen, starch, sucrose, glyoxylate/dicarboxylate metabolism, valine and leucine degradation, and tricarboxylic acid cycle (TCA) were significantly upregulated. By contrast, ribosome biogenesis, pentose/glucuronate interconversion, tryptophan/pyruvate metabolic pathways, and meiosis were significantly downregulated. FBA revealed that a large set of metabolic pathways was altered by imatinib to compensate cancer-associated metabolic changes. Integration of transcriptome and interactome (protein/protein interactions) data helped to identify the core regulatory genes and pathways through elucidation of the active subnetworks. It appears that imatinib may also contribute to antitumoral immune response in the tumor microenvironment and most of the metabolic rearrangements are at posttranscriptional level. Furthermore, additional support for possible contribution of thiamine/pyridoxal phosphate biosynthesis and mitogen-activated protein kinase pathway to drug resistance is noted. This report advances multi-omics understanding of the mechanism of imatinib, and by extension, offers new molecular avenues toward precision medicine and discovery of novel drug targets in cancer therapeutics.
Get full access to this article
View all access options for this article.
References
1.
AgarwalA, EideCA, HarlowA, et al. (2008). An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia, 22, 2269–2272.
2.
AnX, TiwariAK, SunY, DingPR, AshbyCR, and ChenZS. (2010). BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk Res, 34, 1255–1268.
3.
AnanievaEA, and WilkinsonAC. (2018). Branched-chain amino acid metabolism in cancer. Curr Opin Clin Nutr Metab Care, 21, 64–70.
4.
AngsutararuxP, LuanpitpongS, and IssaragrisilS. (2015). Chemotherapy-induced cardiotoxicity: Overview of the roles of oxidative stress. Oxid Med Cell Longev, 2015, 795602.
5.
AungHW, HenrySA, and WalkerLP. (2013). Revising the representation of fatty acid, glycerolipid, and glycerophospholipid metabolism in the consensus model of yeast metabolism. Ind Biotechnol (New Rochelle, NY), 9, 215–228.
BaderG, and HogueC. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4, 2.
8.
BaganzF, HayesA, MarrenD, GardnerDC, and OliverSG. (1997). Suitability of replacement markers for functional analysis studies in Saccharomyces cerevisiae. Yeast, 13, 1563–1573.
9.
BurottoM, ChiouVL, LeeJM, and KohnEC. (2014). The MAPK pathway across different malignancies: A new perspective. Cancer, 120, 3446–3456.
10.
CaoJ, WeiJ, YangP, et al. (2018). Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance. Mol Cancer, 17, 121.
11.
CarlssonP, and MahlapuuM. (2002). Forkhead transcription factors: Key players in development and metabolism. Dev Biol, 250, 1–23.
12.
CatezF, Dalla VeneziaN, MarcelV, ZorbasC, LafontaineDLJ, and DiazJJ. (2019). Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochem Pharmacol, 159, 74–81.
13.
ChangSP, ShenSC, LeeWR, YangLL, and ChenYC. (2011). Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells. J Dermatol Sci, 62, 183–191.
14.
Chang-Yew LeowC, GerondakisS, and SpencerA. (2013). MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J, 3, e105.
15.
ChenCC, LiB, MillmanSE, et al. (2020). Vitamin B6 addiction in acute myeloid leukemia. Cancer Cell, 37, 71–84.e7.
16.
ChuS, HoltzM, GuptaM, and BhatiaR. (2004). BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood, 103, 3167–3174.
17.
CorlessCL, SchroederA, GriffithD, et al. (2005). PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol, 23, 5357–5364.
18.
DeyP, BaddourJ, MullerF, et al. (2017). Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature, 542, 119–123.
19.
Dos SantosSC, MiraNP, MoreiraAS, and Sá-CorreiaI. (2012). Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension. OMICS, 16, 537–551.
20.
dos SantosSC, and Sá-CorreiaI. (2009). Genome-wide identification of genes required for yeast growth under imatinib stress: Vacuolar H+-ATPase function is an important target of this anticancer drug. OMICS, 13, 185–198.
21.
DuckerGS, and RabinowitzJD. (2017). One-carbon metabolism in health and disease. Cell Metab, 25, 27–42.
22.
EmadiE, AbdoliN, GhanbarinejadV, et al. (2019). The potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury. Heliyon, 5, e01996.
23.
EskandariS, and YazdanparastR. (2019). Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib. J Cell Biochem, 120, 10128–10136.
24.
FerreiraR, LimetaA, and NielsenJ. (2019). Tackling cancer with yeast-based technologies. Trends Biotechnol, 37, 592–603.
25.
GottschalkS, AndersonN, HainzC, EckhardtSG, and SerkovaNJ. (2004). Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res, 10, 6661–6668.
26.
HochhausA, O'BrienSG, GuilhotF, et al. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23, 1054–1061.
27.
HuangD, ShermanB, and LempickiR. (2009a). Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research, 37, 1–13.
28.
HuangDW, ShermanBT, and LempickiRA. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44–57.
29.
IqbalN. (2014). Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract, 2014, 357027.
30.
KimJL, LeeDH, JeongS, et al. (2019). Imatinib induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. Oncol Rep, 41, 1616–1626.
31.
KumarK, GhanghasP, and SanyalSN. (2018). Chemopreventive action of Imatinib, a tyrosine kinase inhibitor in the regulation of angiogenesis and apoptosis in rat model of lung cancer. Mol Cell Biochem, 447, 47–61.
32.
LamEW, BrosensJJ, GomesAR, and KooCY. (2013). Forkhead box proteins: Tuning forks for transcriptional harmony. Nat Rev Cancer, 13, 482–495.
33.
LiuM, WangX, WangL, et al. (2018a). Targeting the IDO1 pathway in cancer: From bench to bedside. J Hematol Oncol, 11, 100.
34.
LiuP, TanF, LiuH, LiB, LeiT, and ZhaoX. (2020). The use of molecular subtypes for precision therapy of recurrent and metastatic gastrointestinal stromal tumor. Onco Targets Ther, 13, 2433–2447.
35.
LiuY, SongB, WeiY, et al. (2018b). Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway. Cytotherapy, 20, 181–188.
Martinez-MoralMP, and KannanK. (2019). Allantoin as a marker of oxidative stress: Inter- and intraindividual variability in urinary concentrations in healthy individuals. Environ Sci Technol Lett, 6, 283–288.
38.
MashimaT, SeimiyaH, and TsuruoT. (2009). De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer, 100, 1369–1372.
39.
MayersJR, TorrenceME, DanaiLV, et al. (2016). Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science, 353, 1161–1165.
40.
NewmanAC, and MaddocksODK. (2017). One-carbon metabolism in cancer. Br J Cancer, 116, 1499–1504.
41.
NilssonA, and NielsenJ. (2017). Genome scale metabolic modeling of cancer. Metab Eng, 43, 103–112.
42.
PavlovaNN, and ThompsonCB. (2016). The emerging hallmarks of cancer metabolism. Cell Metab, 23, 27–47.
43.
PoliakováM, AebersoldDM, ZimmerY, and MedováM. (2018). The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Mol Cancer, 17, 27.
44.
RenW, GuanW, ZhangJ, WangF, and XuG. (2019). Pyridoxine 5′-phosphate oxidase is correlated with human breast invasive ductal carcinoma development. Aging (Albany NY), 11, 2151–2176.
45.
RosenzweigSA. (2018). Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res, 138, 71–98.
46.
SabnisHS, BradleyHL, TripathiS, et al. (2016). Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine. Leuk Res, 50, 132–140.
47.
ShahNP, NicollJM, NagarB, et al. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, 117–125.
48.
ShannonP, MarkielA, OzierO, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
49.
StarkC, BreitkreutzB, RegulyT, BoucherL, BreitkreutzA, and TyersM. (2006). BioGRID: A general repository for interaction datasets. Nucleic Acids Res, 34, D535–D539.
50.
SuzukiM, AbeA, ImagamaS, et al. (2010). BCR-ABL-independent and RAS/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol, 84, 229–238.
51.
TakayamaY, KokuryoT, YokoyamaY, et al. (2008). MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett, 264, 241–249.
52.
TakemuraT, NakamuraS, YokotaD, et al. (2010). Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation. J Biol Chem, 285, 6585–6594.
53.
Taymaz-NikerelH, KarabekmezME, EraslanS, and KırdarB. (2018). Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep, 8, 13672.
54.
TeixeiraMC, MonteiroPT, PalmaM, et al. (2018). YEASTRACT: An upgraded database for the analysis of transcription regulatory networks in Saccharomyces cerevisiae. Nucleic Acids Res, 46, D348–D353.
55.
TönjesM, BarbusS, ParkYJ, et al. (2013). BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med, 19, 901–908.
56.
Tracz-GaszewskaZ, and DobrzynP. (2019). Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer. Cancers (Basel), 11, 948.
57.
van BarenN, and Van den EyndeBJ. (2015). Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol, 6, 34.
58.
VargasFA, PizarroF, Pérez-CorreaJR, and AgosinE. (2011). Expanding a dynamic flux balance model of yeast fermentation to genome-scale. BMC Syst Biol, 5, 75.
59.
ZengC, LiuS, LuS, et al. (2018). The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells. Mol Cancer, 17, 130.
60.
ZhangJ, LeiW, ChenX, WangS, and QianW. (2018). Oxidative stress response induced by chemotherapy in leukemia treatment. Mol Clin Oncol, 8, 391–399.
61.
ZhangL, ZhouD, GuanW, et al. (2017). Pyridoxine 5′-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer. Cell Death Dis, 8, 3214.
62.
ZhaoF, MancusoA, BuiTV, et al. (2010). Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene, 29, 2962–2972.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
